Skip to search formSkip to main contentSkip to account menu

TAK 438

Known as: TAK-438, TAK438 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Correction to “1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of…
Proton pump inhibitors (PPIs) are widely used in the treatment of acid-related diseases. However, several unmetmedical needs… 
2016
2016
Discovery of Vonoprazan Fumarate (TAK-438) as a Novel, Potent and Long-Lasting Potassium-Competitive Acid Blocker
2014
2014
Tu1059 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to Lansoprazole (30 mg Once-Daily) in Patients With Erosive…
2013
2013
Mo1054 Does Alpha-Galactosidase Alleviate Irritable Bowel Symptoms?
2013
2013
Mo1053 A Phase 2, Randomized, Double-Blind, Parallel-Group, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety of a Novel Potassium-Competitive Acid Blocker (P-CAB) TAK-438 in…
2010
2010
monofumarate (TAK-438), A Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases. Authors
Proton pump inhibitors (PPIs) are widely used in the treatment of acid-related diseases. However, several unmetmedical needs… 
2010
2010
W1103 Mechanism of Inhibition of the Gastric H+,K+-ATPase by a Novel K+-Competitive Acid Blocker Tak-438
2010
2010
W1091 Effects of Tak-438, a Novel Potassium-Competitive Acid Blocker (P-Cab), on Gastric Acid Secretion in Animals
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)